BR0214499A - Derivados de quinazolina para o tratamento do crescimento anormal das células - Google Patents

Derivados de quinazolina para o tratamento do crescimento anormal das células

Info

Publication number
BR0214499A
BR0214499A BR0214499-9A BR0214499A BR0214499A BR 0214499 A BR0214499 A BR 0214499A BR 0214499 A BR0214499 A BR 0214499A BR 0214499 A BR0214499 A BR 0214499A
Authority
BR
Brazil
Prior art keywords
cell growth
abnormal cell
treatment
quinazoline derivatives
erbb2
Prior art date
Application number
BR0214499-9A
Other languages
English (en)
Inventor
John Charles Kath
James Dale Moyer
Richard Damian Connell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0214499A publication Critical patent/BR0214499A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"DERIVADOS DE QUINAZOLINA PARA O TRATAMENTO DO CRESCIMENTO ANORMAL DAS CéLULAS". Esta invenção diz respeito a derivados de quinazolina úteis no tratamento do crescimento celular anormal, tal como o câncer, em mamíferos. Esta invenção também diz respeito a um método de utilização de tais pequenas moléculas no tratamento do crescimento celular anormal em mamíferos, especialmente humanos, e a composições farmacêuticas que contenham tais compostos. A invenção diz respeito ainda a pequenas moléculas que são seletivas em relação ao receptor erbB2 face ao receptor erbB1, em que o referido inibidor erbB2 tem uma gama de seletividades para o erbB2 face ao erbB1 entre 50 e 1.500.
BR0214499-9A 2001-12-12 2002-11-04 Derivados de quinazolina para o tratamento do crescimento anormal das células BR0214499A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12
PCT/IB2002/004636 WO2003049740A1 (en) 2001-12-12 2002-11-04 Quinazoline derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
BR0214499A true BR0214499A (pt) 2005-05-10

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214499-9A BR0214499A (pt) 2001-12-12 2002-11-04 Derivados de quinazolina para o tratamento do crescimento anormal das células

Country Status (29)

Country Link
US (1) US20030171386A1 (pt)
EP (1) EP1465632A1 (pt)
JP (1) JP4181502B2 (pt)
KR (1) KR20040063948A (pt)
CN (1) CN1602195A (pt)
AP (1) AP2004003058A0 (pt)
AR (1) AR037771A1 (pt)
AU (1) AU2002339687A1 (pt)
BR (1) BR0214499A (pt)
CA (1) CA2469670A1 (pt)
DO (1) DOP2002000545A (pt)
EA (1) EA200400680A1 (pt)
EC (1) ECSP045146A (pt)
GT (1) GT200200273A (pt)
HR (1) HRP20040529A2 (pt)
HU (1) HUP0501069A2 (pt)
IL (1) IL161908A0 (pt)
IS (1) IS7233A (pt)
MA (1) MA27154A1 (pt)
MX (1) MXPA04004107A (pt)
NO (1) NO20042882L (pt)
OA (1) OA12734A (pt)
PA (1) PA8561301A1 (pt)
PE (1) PE20030760A1 (pt)
PL (1) PL373848A1 (pt)
TN (1) TNSN04111A1 (pt)
TW (1) TW200301121A (pt)
WO (1) WO2003049740A1 (pt)
ZA (1) ZA200404264B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
WO2004054585A1 (en) * 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EP1575936A1 (en) * 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
MXPA06001989A (es) * 2003-08-18 2006-05-17 Pfizer Prod Inc Programa de dosificacion para un nuevo agente anticanceroso.
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
BRPI0417213A (pt) * 2003-12-24 2007-02-06 Scios Inc tratamento de gliomas malìgnos com inibidores de tgf-beta
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
WO2006129168A2 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
EP2751285B2 (en) 2011-08-31 2020-04-01 Genentech, Inc. Method for sensitivity testing of a tumour for a egfr kinase inhibitor
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
EP4100412A1 (en) 2020-02-03 2022-12-14 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
CN115052878B (zh) 2020-02-03 2024-07-09 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU5783300A (en) * 1999-07-09 2001-01-30 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
ATE286045T1 (de) * 1999-10-19 2005-01-15 Merck & Co Inc Tyrosin kinaseinhibitoren
DK1292591T3 (da) * 2000-06-22 2005-05-30 Pfizer Prod Inc Bicykliske derivater til behandling af abnorm cellevækst
KR20040065259A (ko) * 2001-12-12 2004-07-21 화이자 프로덕츠 인크. Ｅ-2-메톡시-ｎ-(3-(4-(3-메틸-피리딘-3-일옥시)-페닐아미노)-퀴나졸린-6-일)-알릴)-아세트아미드의 염 형태, 그의제조 방법 및 그의 암 치료에 있어서의 용도

Also Published As

Publication number Publication date
ZA200404264B (en) 2005-08-31
WO2003049740A1 (en) 2003-06-19
AP2004003058A0 (en) 2004-06-30
MA27154A1 (fr) 2005-01-03
NO20042882L (no) 2004-07-07
TNSN04111A1 (fr) 2006-06-01
DOP2002000545A (es) 2003-06-16
AU2002339687A1 (en) 2003-06-23
PL373848A1 (en) 2005-09-19
GT200200273A (es) 2003-10-03
IS7233A (is) 2004-04-26
OA12734A (en) 2006-06-28
KR20040063948A (ko) 2004-07-14
CA2469670A1 (en) 2003-06-19
PA8561301A1 (es) 2003-12-30
ECSP045146A (es) 2004-07-23
AR037771A1 (es) 2004-12-01
HRP20040529A2 (en) 2004-10-31
CN1602195A (zh) 2005-03-30
PE20030760A1 (es) 2003-09-05
JP4181502B2 (ja) 2008-11-19
US20030171386A1 (en) 2003-09-11
EP1465632A1 (en) 2004-10-13
MXPA04004107A (es) 2004-07-23
HUP0501069A2 (en) 2006-06-28
EA200400680A1 (ru) 2005-06-30
IL161908A0 (en) 2005-11-20
TW200301121A (en) 2003-07-01
JP2005527486A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
BR0214499A (pt) Derivados de quinazolina para o tratamento do crescimento anormal das células
BR0014384A (pt) Compostos para o tratamento da isquémia
UY25794A1 (es) Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a
BR0312464A (pt) Inibidores de tirosina quinases
AR024138A1 (es) Inhibidores de la proliferacion celular
BRPI0414533A (pt) composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
BG63122B1 (en) Compounds and methods for cancer treatment
BR0200782A (pt) Compostos para o tratamento da isquemia
ES2081334T3 (es) Sulfonilaminocarboniltriazolinonas halogenadas.
BRPI0416190A (pt) combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
ATE253039T1 (de) Beta 2 -adrenergische rezeptor-agonisten
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
BR9916584A (pt) Derivados 3-azabiciclo[3.1.0]hexano úteis em terapia
PT1200412E (pt) Agentes anti-proliferativos de imidazole
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
BRPI0511138A (pt) derivados de pirimidina para o tratamento de desenvolvimento celular anormal
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
IL151692A0 (en) Polyamine analogues as cytotoxic agents
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.